血型鉴定及不规则抗体筛查质控品系公司新增质控品产品，主要用于监测实验室检测系统的稳定状态， 提高检测质量。新产品取得注册证进一步丰富了公司产品项目菜单，有助于提升公司市场综合竞争力， 对市场的拓展以及公司未来的经营将产生积极影响。 迈克生物(300463.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》(体外 诊断试剂)，该产品为："血型鉴定及不规则抗体筛查质控品"。 ...

血型鉴定及不规则抗体筛查质控品系公司新增质控品产品，主要用于监测实验室检测系统的稳定状态， 提高检测质量。新产品取得注册证进一步丰富了公司产品项目菜单，有助于提升公司市场综合竞争力， 对市场的拓展以及公司未来的经营将产生积极影响。 智通财经APP讯，迈克生物(300463.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器 械注册证》(体外诊断试剂)，该产品为："血型鉴定及不规则抗体筛查质控品"。 ...

Core Viewpoint - The announcement indicates that the company has received a medical device registration certificate from the National Medical Products Administration for its blood type identification and irregular antibody screening quality control products, which is expected to enhance its market competitiveness and future operations [1] Group 1: Product Development - The new product registration enriches the company's product portfolio, potentially aiding in market expansion [1] - The actual sales performance of the registered products will depend on future market promotion efforts [1] Group 2: Market Impact - The registration certificate is anticipated to have a positive impact on the company's overall market competitiveness [1] - The future revenue impact of the new product remains unpredictable at this stage [1]

迈克生物股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局颁发的《医 疗器械注册证》（体外诊断试剂），具体情况如下： 证券代码:300463 证券简称:迈克生物 公告编号:2025-105 血型鉴定及不规则抗体筛查质控品系公司新增质控品产品，主要用于监测实验室检测系统 的稳定状态，提高检测质量。新产品取得注册证进一步丰富了公司产品项目菜单，有助于提升 公司市场综合竞争力，对市场的拓展以及公司未来的经营将产生积极影响。 三、风险提示 上述注册证书涉及的产品实际销售情况取决于未来市场推广效果，目前尚无法预测该产品 对公司未来营业收入的影响，敬请广大投资者注意投资风险。 特此公告。 迈克生物股份有限公司 董事会 二〇二五年十二月一日 一、产品注册证具体情况 | 产品名称 | 注册证书 | 注册 | | 注册证有效期 | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 编号 ...

迈克生物股份有限公司 由于迈克生物股份有限公司（以下简称"公司"）天府国际生物城 IVD 产业园陆续开始投 入使用，公司办公地址、邮政编码、投资者联系电话、传真发生变更。除上述变更外，公司网 址、电子邮箱等其他联系方式保持不变。 本次变更后公司最新联系方式如下： | 联系方式 | 变更前 | | 变更后 | | | --- | --- | --- | --- | --- | | 办公地址 | 四川省成都市高新区安和二路 | 8 号 | 四川省成都市双流区岐黄一路 | 1006 号 | | 邮政编码 | 611730 | | 610219 | | | 投资者热线 | 028-81731186 | | 028-61619001 | | | 传真 | 028-81731188 | | 028-61619003 | | | 公司网址 | | https://www.maccura.com/ | | | | 电子邮箱 | | zqb@maccura.com | | | 公司董事会秘书和证券事务代表联系地址、联系电话、信息披露文件备置地点同时变更。 以上变更信息自公告披露之日起正式启用，敬请广大投资者注意上述信息变更事项 ...

Summary of Key Points Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and market dynamics [1] Shareholder Reductions - Southern Precision's actual controller's concerted action party plans to reduce holdings by no more than 2.54% [1] - Huasheng Lithium's shareholder Dunxing Value intends to reduce holdings by up to 0.63% [1] - Yibo Technology's shareholder Lingyu Jicheng plans to reduce holdings by no more than 2.9834% [1] - Hesheng Co., Ltd. has multiple shareholders intending to collectively reduce holdings by no more than 3% [1] - Maike Biological's shareholder Guo Lei plans to reduce holdings by no more than 500,000 shares [1] - Chengyi Pharmaceutical's shareholders Chengyi Small Loan and Yan Xiaoling have completed a reduction of 3.8756 million shares [1] - Guoji Heavy Equipment's shareholders from Bank of China Deyang Branch and Bank of China Zhenjiang Runzhou Branch have collectively reduced holdings by 72.1355 million shares [1] - Debang Technology's shareholder National Integrated Circuit Fund has completed a reduction of 2.8448 million shares [1] - Other notable reductions include: - Yalian Youzhan's shareholder Qian Dejing reducing 0.5476% of company shares [1] - Feile Audio's Lingang Group reducing 24.569 million shares [1] - New Sharp's shareholder Xinhong Zhongfu planning to reduce up to 0.50% of shares [1] - Microchip Biotech's shareholder Boao Bio completing a reduction of 3% of company shares [1] - Zhejiang Zhongcheng's shareholder Chen Jian reducing 11.497 million shares [1] Other Notable Events - ST Dongdi is facing a proposed termination of its stock listing by the Shenzhen Stock Exchange [1] - ST Yatai's stock trading is subject to additional delisting risk warnings [1]

Core Viewpoint - The company is actively integrating AI technologies, such as DeepSeek, into its clinical testing and auxiliary detection systems to enhance efficiency and accuracy in medical data research [1] Group 1: AI Integration - The company utilizes various AI models, including DeepSeek and Tongyi Qianwen, to improve detection efficiency and accuracy in different testing scenarios [1] - The company aims to deepen the application of AI technology in the in vitro diagnostic field, promoting product innovation to meet market demands for efficient and precise testing [1] Group 2: Market Response - The company expresses gratitude for investor support and emphasizes the importance of rational investment decisions regarding AI and medical-related business developments [1]

迈克生物（300463）(300463.SZ)发布公告，公司于近日收到公司持股5%以上股东郭雷先生出具的《关 于计划减持公司股份告知函》，计划自公告披露之日起15个交易日后的三个月内进行，合计通过集中竞 价方式减持不超过50万股公司股份，即不超过公司当前总股本的0.08%。 ...

Core Viewpoint - The company, Maike Biological (300463.SZ), announced that a major shareholder, Mr. Guo Lei, plans to reduce his stake in the company by selling up to 500,000 shares, which represents 0.08% of the total share capital [1] Summary by Categories Shareholder Actions - Mr. Guo Lei, a shareholder holding more than 5% of the company's shares, has issued a notice regarding his plan to reduce his holdings [1] - The planned reduction will occur within three months, starting 15 trading days after the announcement [1] Share Reduction Details - The total number of shares to be sold is capped at 500,000 [1] - This reduction is equivalent to a maximum of 0.08% of the company's current total share capital [1]

南财智讯11月26日电，迈克生物公告，持股5%以上股东郭雷先生计划自本公告披露之日起15个交易日 后的三个月内，通过集中竞价方式减持不超过500,000股公司股份，即不超过公司当前总股本的0.08%。 截至本公告披露日，郭雷先生持有公司股份30,324,906股，占公司当前总股本的5.02%。本次减持原因 为个人资金需求，股份来源为首发前持有股份因资本公积转增股本取得的股份及上市后通过集中竞价方 式增持的股份。减持期间为2025年12月18日至2026年3月17日，减持价格将根据市场价格确定。本次减 持计划不存在深圳证券交易所《上市公司自律监管指引第18号——股东及董事、高级管理人员减持股 份》第五条至第九条规定的情形。公司将按照相关规定披露本次减持计划的实施进展情况。 ...